 IMARA Inc. IMRA, a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the launch of its Real Impact community support initiative. This program will include grant funding to support nonprofit, community-based organizations CBOs serving patients and families impacted by sickle cell disease SCD and beta-thalassemia. In 2020, Imara will fund between 15 and 20 grants totaling up to 100,000 across three key areas: social health impact programs, COVID-19 relief programs and organizational capacity enhancement programs. 